Management is cutting an additional 4,000 jobs, bringing total restructuring reductions to approximately 13,000. This diversification effort follows a Phase 3 trial in which CagriSema delivered 12.4% weight loss at 60 weeks, beating Eli Lilly's tirzepatide at 9.1%. In the U.S. market, the Wegovy pill has reached 7 million prescriptions, with 90% of those sales occurring through self pay channels rather than insurance.
Wednesday, October 21, 2026
Story
Novo Nordisk Shares Drop 7.4% After Long Term Plan Fails Investors
Earnings30 days ago
The Danish pharmaceutical company's American Depositary Receipts hit a session low on Monday after management unveiled a strategy to launch at least five multi-blockbuster drugs by 2030. Novo Nordisk targets more than $23 billion in risk adjusted pipeline sales by 2035 and 10 Phase 3 programs across obesity, diabetes, and other diseases to offset the 2032 loss of U.S. exclusivity for semaglutide. The company aims to serve 60 million patients globally by the end of the decade while maintaining broadly stable operating margins.
Looking for more context or analysis?
Tilt chat provides reliable, tailored insights, alerts, and automations.